Real-World Achievement of Skin Clearance Targets and Improved Quality of Life With Risankizumab in Psoriasis Patients With Moderate Skin Involvement (BSA ≥ 3–10%). J of Skin [Internet]. 2024 Nov. 18 [cited 2025 May 18];8(6):s421. Available from: https://skin.dermsquared.com/skin/article/view/3087